The Impact of Semaglutide on Weight Loss and Inflammation in People with HIV. An Observational Prospective Study in Greek Population.

Petrakis V, Rafailidis P, Panopoulou M, Konstantinidis T, Tsantes AG, Babaka N, Papazoglou D, Panagopoulos P

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association4 Nov 2025Cited by 1 (Europe PMC)

PMID41187787DOI10.1055/a-2737-6227PepBankPUB-41187787

Publisher page PubMedAsk about this study

Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanObservational studyEfficacy outcome
In people with HIV and type 2 diabetes, semaglutide produced significant and sustained weight loss.
In plain wordsIn people with HIV and type 2 diabetes, semaglutide led to lasting weight loss.
Peptide
Semaglutide
Outcome
DecreaseWeight loss in people with HIV
Study
n = 25
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
gradual increase to 1 mg once weekly · 24 monthsAs given in this study (human).
Source sentences
Summary
Semaglutide treatment resulted in significant and sustained weight loss in both groups (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals.
Report a problemFND-4118778701
02HumanObservational studyEfficacy outcome
In matched people without HIV who had type 2 diabetes, semaglutide produced significant and sustained weight loss.
In plain wordsIn people without HIV who had type 2 diabetes, semaglutide led to lasting weight loss.
Peptide
Semaglutide
Outcome
DecreaseWeight loss in non-HIV controls
Study
n = 25
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
gradual increase to 1 mg once weekly · 24 monthsAs given in this study (human).
Source sentences
Summary
Semaglutide treatment resulted in significant and sustained weight loss in both groups (p<0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals.
Report a problemFND-4118778702
03HumanObservational studyEfficacy outcome
In people with HIV and type 2 diabetes, mean HbA1c fell significantly on semaglutide.
In plain wordsIn people with HIV and type 2 diabetes, blood sugar control (HbA1c) improved significantly on semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change in people with HIV
Study
n = 25
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
gradual increase to 1 mg once weekly · 24 monthsAs given in this study (human).
Measurements
HbA1c, before
7.7%
people with HIV
HbA1c, after
5.2%
people with HIV
Source sentences
Summary
Glycemic control also improved significantly, with mean HbA1c decreasing from 7.7%±1.23 to 5.2%±1.02 in PWH (p<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals.
Report a problemFND-4118778705
04HumanObservational studyEfficacy outcome
In people without HIV who had type 2 diabetes, mean HbA1c fell significantly on semaglutide.
In plain wordsIn people without HIV who had type 2 diabetes, blood sugar control (HbA1c) improved significantly on semaglutide.
Peptide
Semaglutide
Outcome
DecreaseHbA1c change in non-HIV controls
Study
n = 25
Comparator
Baseline
Outcome group
Glycemic control · Metabolic and weight
Studied dose
gradual increase to 1 mg once weekly · 24 monthsAs given in this study (human).
Measurements
HbA1c, before
7.9%
non-HIV controls
HbA1c, after
5.6%
non-HIV controls
Source sentences
Summary
and from 7.9%±1.16 to 5.6%±1.21 in non-HIV controls (p<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals.
Report a problemFND-4118778706
05HumanObservational studyEfficacy outcome
In people with HIV and type 2 diabetes, hsCRP fell significantly on semaglutide.
In plain wordsIn people with HIV and type 2 diabetes, the inflammation marker hsCRP fell significantly on semaglutide.
Peptide
Semaglutide
Outcome
DecreasehsCRP change in people with HIV
Study
n = 25
Comparator
Baseline
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
gradual increase to 1 mg once weekly · 24 monthsAs given in this study (human).
Source sentences
Summary
Significant reductions were observed in hsCRP and sCD14 levels in both cohorts.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals.
Report a problemFND-4118778707
06HumanObservational studyEfficacy outcome
In people without HIV who had type 2 diabetes, hsCRP fell significantly on semaglutide.
In plain wordsIn people without HIV who had type 2 diabetes, the inflammation marker hsCRP fell significantly on semaglutide.
Peptide
Semaglutide
Outcome
DecreasehsCRP change in non-HIV controls
Study
n = 25
Comparator
Baseline
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
gradual increase to 1 mg once weekly · 24 monthsAs given in this study (human).
Source sentences
Summary
Significant reductions were observed in hsCRP and sCD14 levels in both cohorts.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals.
Report a problemFND-4118778708
07HumanObservational studyEfficacy outcome
In people with HIV and type 2 diabetes, sCD14 fell significantly on semaglutide.
In plain wordsIn people with HIV and type 2 diabetes, the inflammation marker sCD14 fell significantly on semaglutide.
Peptide
Semaglutide
Outcome
DecreasesCD14 change in people with HIV
Study
n = 25
Comparator
Baseline
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
gradual increase to 1 mg once weekly · 24 monthsAs given in this study (human).
Source sentences
Summary
Significant reductions were observed in hsCRP and sCD14 levels in both cohorts.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals.
Report a problemFND-4118778709
08HumanObservational studyEfficacy outcome
In people without HIV who had type 2 diabetes, sCD14 fell significantly on semaglutide.
In plain wordsIn people without HIV who had type 2 diabetes, the inflammation marker sCD14 fell significantly on semaglutide.
Peptide
Semaglutide
Outcome
DecreasesCD14 change in non-HIV controls
Study
n = 25
Comparator
Baseline
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
gradual increase to 1 mg once weekly · 24 monthsAs given in this study (human).
Source sentences
Summary
Significant reductions were observed in hsCRP and sCD14 levels in both cohorts.
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals.
Report a problemFND-4118778710
09HumanObservational studyEfficacy outcome
In people with HIV and type 2 diabetes, the CD4/CD8 ratio rose significantly over 24 months of semaglutide.
In plain wordsIn people with HIV and type 2 diabetes, the CD4/CD8 immune cell ratio rose significantly over 24 months of semaglutide.
Peptide
Semaglutide
Outcome
IncreaseCD4/CD8 ratio in people with HIV
Study
n = 25
Comparator
Baseline
Outcome group
Immune response · Immune and inflammation
Studied dose
gradual increase to 1 mg once weekly · 24 monthsAs given in this study (human).
Measurements
CD4/CD8 ratio, baseline
0.54 ratio
people with HIV
CD4/CD8 ratio, 24 months
0.83 ratio
people with HIV
Source sentences
Summary
A unique finding was the significant increase in the CD4/CD8 ratio in the PWH group, from a mean baseline of 0.54±0.12 to 0.83±0.14 at 24 months (p<0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals.
Report a problemFND-4118778711
10HumanObservational studyEfficacy outcome
In people without HIV who had type 2 diabetes, the CD4/CD8 ratio did not change significantly on semaglutide.
In plain wordsIn people without HIV who had type 2 diabetes, the CD4/CD8 immune cell ratio did not change significantly on semaglutide.
Peptide
Semaglutide
Outcome
No significant changeCD4/CD8 ratio in non-HIV controls
Study
n = 25
Comparator
Baseline
Outcome group
Immune response · Immune and inflammation
Studied dose
gradual increase to 1 mg once weekly · 24 monthsAs given in this study (human).
Source sentences
Summary
a change not seen in the non-HIV controls
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals.
Report a problemFND-4118778712
11HumanObservational studyEfficacy outcome
In people with HIV and a baseline BMI above 35, median weight loss at 24 months on semaglutide was 14.6 kg.
In plain wordsIn people with HIV and a baseline BMI above 35, median weight loss at 24 months on semaglutide was 14.6 kg.
Peptide
Semaglutide
Outcome
DecreaseMedian weight loss at 24 months, baseline BMI above 35, people with HIV
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
gradual increase to 1 mg once weekly · 24 monthsAs given in this study (human).
Measurements
Median weight loss
−14.6 kg
people with HIV, baseline BMI>35
Source sentences
Summary
At 24 months, the median weight loss was -14.6 kg in the PWH group
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals.
Report a problemFND-4118778703
12HumanObservational studyEfficacy outcome
In people without HIV and a baseline BMI above 35, median weight loss at 24 months on semaglutide was 18.8 kg.
In plain wordsIn people without HIV and a baseline BMI above 35, median weight loss at 24 months on semaglutide was 18.8 kg.
Peptide
Semaglutide
Outcome
DecreaseMedian weight loss at 24 months, baseline BMI above 35, non-HIV controls
Study
n: not reported in source
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Studied dose
gradual increase to 1 mg once weekly · 24 monthsAs given in this study (human).
Measurements
Median weight loss
−18.8 kg
non-HIV controls, baseline BMI>35
Source sentences
Summary
At 24 months, the median weight loss was -14.6 kg in the PWH group and -18.8 kg in the non-HIV group
1 context sentence(design, population, supporting numbers)
Summary · context
In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated.This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals.
Report a problemFND-4118778704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.